Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-101 for negative symptoms of schizophrenia
2014-004878-42Phase 2Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roluperidone in schizophrenia (3 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoint: Change from baseline in PANSS negative subscale. Started Dec 2014; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2014-004878-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004878-42.